Barclays’s LeMaitre Vascular LMAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $474K | Sell |
4,942
-10,051
| -67% | -$1.03M | ﹤0.01% | 3260 |
|
|
2026
Q1 | $1.64M | Sell |
14,993
-17,565
| -54% | -$1.67M | ﹤0.01% | 2483 |
|
|
2025
Q4 | $2.64M | Buy |
32,558
+2,560
| +9% | +$220K | ﹤0.01% | 2725 |
|
|
2025
Q3 | $2.63M | Sell |
29,998
-10,728
| -26% | -$958K | ﹤0.01% | 2676 |
|
|
2025
Q2 | $3.38M | Buy |
40,726
+12,177
| +43% | +$1.02M | ﹤0.01% | 2429 |
|
|
2025
Q1 | $2.4M | Sell |
28,549
-9,825
| -26% | -$914K | ﹤0.01% | 2493 |
|
|
2024
Q4 | $3.54M | Buy |
38,374
+1,797
| +5% | +$173K | ﹤0.01% | 2457 |
|
|
2024
Q3 | $3.4M | Buy |
36,577
+29,180
| +394% | +$2.53M | ﹤0.01% | 2415 |
|
|
2024
Q2 | $609K | Sell |
7,397
-10,551
| -59% | -$775K | ﹤0.01% | 2922 |
|
|
2024
Q1 | $1.19M | Sell |
17,948
-13,256
| -42% | -$818K | ﹤0.01% | 2980 |
|
|
2023
Q4 | $1.77M | Buy |
31,204
+21,534
| +223% | +$1.13M | ﹤0.01% | 3012 |
|
|
2023
Q3 | $527K | Sell |
9,670
-583
| -6% | -$34.6K | ﹤0.01% | 2778 |
|
|
2023
Q2 | $690K | Buy |
10,253
+370
| +4% | +$22.6K | ﹤0.01% | 2555 |
|
|
2023
Q1 | $509K | Sell |
9,883
-10,996
| -53% | -$534K | ﹤0.01% | 3265 |
|
|
2022
Q4 | $961K | Sell |
20,879
-346
| -2% | -$16.2K | ﹤0.01% | 2843 |
|
|
2022
Q3 | $1.07M | Sell |
21,225
-1,488
| -7% | -$74.4K | ﹤0.01% | 2176 |
|
|
2022
Q2 | $1.03M | Sell |
22,713
-5,751
| -20% | -$257K | ﹤0.01% | 2320 |
|
|
2022
Q1 | $1.32M | Buy |
28,464
+3,733
| +15% | +$167K | ﹤0.01% | 2187 |
|
|
2021
Q4 | $1.24M | Sell |
24,731
-3,326
| -12% | -$172K | ﹤0.01% | 2686 |
|
|
2021
Q3 | $1.49M | Buy |
28,057
+16,126
| +135% | +$908K | ﹤0.01% | 2534 |
|
|
2021
Q2 | $728K | Sell |
11,931
-13,769
| -54% | -$731K | ﹤0.01% | 2857 |
|
|
2021
Q1 | $1.25M | Buy |
25,700
+6,406
| +33% | +$300K | ﹤0.01% | 2634 |
|
|
2020
Q4 | $781K | Sell |
19,294
-1,025
| -5% | -$36.6K | ﹤0.01% | 2938 |
|
|
2020
Q3 | $660K | Buy |
20,319
+5,247
| +35% | +$158K | ﹤0.01% | 3021 |
|
|
2020
Q2 | $398K | Buy |
15,072
+1,410
| +10% | +$36.9K | ﹤0.01% | 3533 |
|
|
2020
Q1 | $340K | Sell |
13,662
-10,944
| -44% | -$338K | ﹤0.01% | 3890 |
|
|
2019
Q4 | $884K | Buy |
24,606
+5,953
| +32% | +$205K | ﹤0.01% | 3786 |
|
|
2019
Q3 | $637K | Sell |
18,653
-5,546
| -23% | -$177K | ﹤0.01% | 4043 |
|
|
2019
Q2 | $677K | Buy |
24,199
+13,494
| +126% | +$375K | ﹤0.01% | 4069 |
|
|
2019
Q1 | $332K | Buy |
10,705
+4,065
| +61% | +$108K | ﹤0.01% | 4436 |
|
|
2018
Q4 | $157K | Sell |
6,640
-18,727
| -74% | -$511K | ﹤0.01% | 4745 |
|
|
2018
Q3 | $982K | Buy |
25,367
+4,669
| +23% | +$168K | ﹤0.01% | 3633 |
|
|
2018
Q2 | $692K | Buy |
20,698
+6,042
| +41% | +$215K | ﹤0.01% | 3636 |
|
|
2018
Q1 | $530K | Sell |
14,656
-7,259
| -33% | -$251K | ﹤0.01% | 3918 |
|
|
2017
Q4 | $698K | Buy |
21,915
+6,267
| +40% | +$215K | ﹤0.01% | 3481 |
|
|
2017
Q3 | $585K | Buy |
15,648
+5,428
| +53% | +$185K | ﹤0.01% | 3462 |
|
|
2017
Q2 | $318K | Buy |
10,220
+874
| +9% | +$25.2K | ﹤0.01% | 3943 |
|
|
2017
Q1 | $231K | Buy |
+9,346
| New | +$219K | ﹤0.01% | 4168 |
|
|
2016
Q4 | – | Sell |
-1
| Closed | – | – | 6730 |
|
|
2016
Q3 | $0 | Buy |
+1
| New | +$17 | ﹤0.01% | 6708 |
|
|
2016
Q2 | – | Sell |
-11,000
| Closed | -$165K | – | 6477 |
|
|
2016
Q1 | $165K | Buy |
+11,000
| New | +$158K | ﹤0.01% | 3978 |
|
|
2015
Q4 | – | Sell |
-62
| Closed | -$1K | – | 6300 |
|
|
2015
Q3 | $1K | Sell |
62
-165
| -73% | -$2.12K | ﹤0.01% | 6554 |
|
|
2015
Q2 | $3K | Buy |
+227
| New | +$2.23K | ﹤0.01% | 6682 |
|
Other funds holding LMAT
CCA
CAM
CCM
Barclays's LMAT Position: Q2 2026 in Review
Barclays reduced its LeMaitre Vascular (LMAT) stake by 67% in Q2 2026, selling an estimated $1.03M and leaving 4,942 shares worth $474K. The position accounts for ﹤0.01% of the portfolio, ranked #3260.
Barclays first reported a position in LMAT in Q2 2015 and has held it in 42 quarters since. The position peaked at $3.54M in Q4 2024. 326 funds tracked by Wall St. Rank hold LMAT as of Q2 2026.
- Barclays held 4,942 shares of LeMaitre Vascular worth $474K as of Q2 2026.
- Barclays sold 10,051 LeMaitre Vascular shares in Q2 2026, an estimated $1.03M.
- LeMaitre Vascular made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3260 holding.
- Barclays first reported a position in LeMaitre Vascular in Q2 2015 and has held it in 42 quarters since.
- Barclays's LeMaitre Vascular position peaked at $3.54M in Q4 2024.
- 326 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.